Global Pericarditis Market - 2023-2030
Global Pericarditis Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Pericarditis is caused by inflammation of the pericardium, the lining of the heart, mainly driven by viruses, inflammatory diseases like lupus, and rheumatoid arthritis. Anti-inflammatory agents and corticosteroids are used for the treatment of pericarditis. Based on its duration, it is of two types, acute and chronic pericarditis. It is also seen in COVID patients as it is caused by flu infection.
According to the National Center for Biotechnology Information, the incidence of acute pericarditis in the general population is approximately 27.7 cases per 100,000 individuals annually. However, pericarditis infection has many causes, such as viral, bacterial, fungal, etc. The symptoms don't vary much. It causes chest pain, sweating, and breathlessness in almost every individual.Market Dynamics
: Drivers & Restraints
Increasing prevalence of virus-associated pericarditis
Viral infections are a leading cause of pericarditis worldwide, as the condition frequently coexists with viral infections. According to Harvard Health, the initial trigger for pericarditis is viral infections, as they cause fluid accumulation in various organs, including the heart. Treatment is more feasible than prevention because the cause of the disease is dependent on many factors, such as viruses, bacteria, autoimmune disorders, etc.
According to the World Health Organisation 2022 issue, every year, an estimated 650,000 deaths are caused due to respiratory diseases linked to seasonal influenza alone. Influenza leads to pericarditis as the infection moves to the heart and causes inflammation in the pericardium.
COVID-19 also reported pericarditis cases as the flu spread to almost every part of the body and caused inflammation. As of December 2022, 6,618,579 COVID deaths have been reported, most of which had heart inflammation. For instance, according to the AHA journal 2023 issue, SARS-CoV-2 increased the incidence of myocarditis/pericarditis by at least 15× over pre-COVID levels, although the condition remains rare.
Furthermore, increased prevalence of heart diseases, increased innovations, and advancements in better diagnosis and treatment are the factors that drive the market in the forthcoming period.
Side effects of pericardiectomy
Side effects of Pericardiectomy include excessive bleeding, atrial and ventricular arrhythmia, and even ventricular wall rupture. Blood clots and infection are also observed in a few patients undergoing Pericardiectomy. Overcoming these risks is difficult as the procedures are risky to perform. Hence, most pericarditis cases are treated using anti-inflammatory drugs, which causes fewer side effects that are often treatable.Segment Analysis
The global pericarditis market is segmented based on disease type, treatment type, end user and region.
The Anti inflammatory drugs segment accounted for approximately 45.8% of the market share
Anti-inflammatory drugs are the first-line treatment for pericarditis. Companies are currently working on the same with increased efficacy and safety. The United States Food and Drug Administration is supporting Cardiol Therapeutics Inc. in conducting two Phase II studies in rare heart diseases, recurrent pericarditis, and acute myocarditis, as no other drugs are currently discovered for rare heart diseases like pericarditis.
In November 2022, Cardiol Therapeutics Inc. declared positive results demonstrating the protective effects of CardiolRx. It significantly reduces pericardial effusion and thickening of the pericardium.
In January 2023, Cardiol Therapeutics Inc. declared that the first patient had been enrolled in the company-sponsored Phase II study evaluating the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis.
North America accounted for approximately 40.6% of the market share in 2022
North America is expected to hold the largest market share due to the incidence of pericarditis in patients who received vaccines developed by U.S. companies. Pericarditis causes heart failure that affects more than 64 million people globally, and associated healthcare costs exceed $30 billion annually in the U.S. alone. The disease is diagnosed in 0.2% of all cardiovascular in-hospital admissions and is responsible for 5% of emergency room admissions for chest pain in North America and Western Europe.
More than 22 million doses of Moderna have been administered in Canada, where the incidence of myocarditis, pericarditis, or myopericarditis is two to threefold higher after a second dose of the Moderna Spikevax COVID-19 vaccine than the Pfizer vaccine. Forty-one pericarditis cases were immediately observed after the Moderna vaccine in Canada.COVID-19 Impact Analysis
Covid 19 had a slight, moderate impact on the pericarditis market. The supply chains were interrupted during the peak period of the infection. Most of the diagnostic centers were shut down due to the implementation of lockdowns worldwide. This impacted the diagnosis and, thus, treatment procedures for cardiovascular diseases, including pericarditis.
Many of them were postponed and diagnosed at later stages as there are many types of pericarditis with different causes; the treatment options vary, with individuals requiring extensive testing that was shut down entirely during the 19 period. Hence, all the research focused on vaccines and covid drug development.Competitive Landscape
The major global players in the pericarditis market include Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Merck KGaA, Cumberland Pharmaceuticals Inc., Johnson & Johnson Inc., Bayer AG, Midas Pharma GmbH., Alchem International Pvt. Ltd., Takeda Pharmaceutical Company Limited, Azure Pharmaceuticals among others.
• Rabin Medical Center is conducting phase 4 clinical trials to compare the efficacy of NSAID therapy and Dexamethasone therapy in patients suffering from pericarditis. The study start date is February 14, 2020. The estimated completion date is December 2023.
• In March 2021, Kiniksa Pharmaceuticals, Ltd. received the U.S. Food and Drug Administration (FDA) approval for ARCALYST for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. It was commercially launched in August 2021.Why Purchase the Report?
• To visualize the global pericarditis market segmentation based on disease type, treatment type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pericarditis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global pericarditis market report would provide approximately 63 tables, 65 figures, and 195 Pages.Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies